Compare INAB & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INAB | PRSO |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 13.4M |
| IPO Year | 2020 | 2000 |
| Metric | INAB | PRSO |
|---|---|---|
| Price | $1.10 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 71.6K | ★ 298.9K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.23 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,573,000.00 |
| Revenue This Year | N/A | $18.48 |
| Revenue Next Year | N/A | $53.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.99 |
| 52 Week Low | $0.88 | $0.58 |
| 52 Week High | $2.73 | $2.37 |
| Indicator | INAB | PRSO |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 40.20 |
| Support Level | N/A | $0.58 |
| Resistance Level | $1.50 | $0.94 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 70.36 | 41.34 |
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.